Mitsubishi Tanabe Pharma Corporation

Mitsubishi Pharma Corporation

Mitsubishi-Tokyo Pharmaceuticals, Inc.

Toshifumi Matsumoto

Hiroyuki Satoh

Masakazu Fujio

Shinya Inoue

Yasuhiro Egi

Nobuyuki Yasuda

Hiroyuki Iizuka

Taichi Takahashi

Kouichi Matsunaga

Susumu Tsuchiya

Kozo Hiratsuka

Atsusi Hukuzaki

The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.

Isoquinoline compound and pharmaceutical use thereof

The present invention relates to an isoquinoline compound represented by the following formula (I) or (II), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. 

Isoquinoline compounds and medicinal use thereof

Phenylethanolamine compounds useful as .beta. 3 agonists, process for

Growing community of inventors

Tokyo, Japan

Toshifumi Matsumoto